| Type | Title | Date Released | |
|---|---|---|---|
8-K | Genprex Announces Results from Translational Analysis of REQORSA at GSA 2026 Annual Scientific Meeting | ||
8-K | Genprex to Present New Research on TROP2 as a Potential Predictive Biomarker for REQORSA at the 2026 EORTC-NCI-AACR Symposium | ||
8-K | Genprex Announces Research from Meharry Medical College Collaboration to be Featured at Gerontological Society of America 2026 Annual Scientific Meeting | ||
8-K | Peer-reviewed mouse study links TUSC2 loss to mitochondrial dysfunction, impaired protein homeostasis, and sex-specific hippocampal aging changes | ||
8-K | Genprex Enters Manufacturing Agreement to Scale Diabetes Gene Therapy Program | ||
10-Q | Form 10-Q | ||
8-K | Genprex, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement | ||
8-K | Genprex Announces Collaboration with Roche Diagnostics to Validate NSCLC Biomarkers | ||
8-K | Genprex, Inc. Granted Nasdaq Listing Exception Following Bid Price Deficiency | ||
8-K | Genprex, Inc. Announces 1-for-22 Reverse Stock Split to Regain Nasdaq Compliance | ||
S-8 | Form S-8 | ||
8-K | Genprex Receives Canadian Patent Allowance for REQORSA® Gene Therapy Combinations |